Impact of Ramadan on Achieving Joint National Committee (JNC) 7 Treatment Goals in CV Risk Patients
- Conditions
- Hypertension
- First Posted Date
- 2013-05-15
- Last Posted Date
- 2015-08-10
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1674
- Registration Number
- NCT01853839
- Locations
- 🇩🇿
Boehringer Ingelheim Investigational Site 109, Algiers, Algeria
🇩🇿Boehringer Ingelheim Investigational Site 110, Algiers, Algeria
🇩🇿Boehringer Ingelheim Investigational Site 123, Algiers, Algeria
Comparative Effectiveness of Oral Anticoagulants
- Conditions
- Atrial Fibrillation
- First Posted Date
- 2013-05-07
- Last Posted Date
- 2014-06-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 5982
- Registration Number
- NCT01847547
Anticoagulant Utilization Pattern
- Conditions
- Atrial Fibrillation
- First Posted Date
- 2013-05-07
- Last Posted Date
- 2019-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 333664
- Registration Number
- NCT01847560
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Relative Bioavailability of 2 Fixed Dose Combinations of Linagliptin/Metformin Compared With Single Tablets
- Conditions
- Healthy
- Interventions
- Drug: 2x500 mg Metformin (Glumetza)Drug: 2 x 2.5 mg Linagliptin/750 mg Metformin FDCDrug: 5 mg Linagliptin/1000 mg Metformin FDCDrug: 3x500 mg Metformin (Glumetza)Drug: 5 mg Linagliptin/1000mg Metformin FDCDrug: 2 x 500 mg Metformin (Glumetza)
- First Posted Date
- 2013-05-03
- Last Posted Date
- 2014-08-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 72
- Registration Number
- NCT01845077
- Locations
- 🇺🇸
1288.8.1 Boehringer Ingelheim Investigational Site, Austin, Texas, United States
Bioequivalence of Empagliflozin and Metformin Given as a Fixed Dose Combination Compared to Single Tablets
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2013-05-01
- Last Posted Date
- 2015-07-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT01844531
- Locations
- 🇩🇪
1276.6.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Safety of Single Rising Doses and Relative Bioavailability of BI 691751
- First Posted Date
- 2013-05-01
- Last Posted Date
- 2016-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 81
- Registration Number
- NCT01843972
- Locations
- 🇩🇪
1334.1.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Safety, Tolerability and Pharmacokinetics of BI 409306 Tablets in Healthy Asian Male Volunteers
- Conditions
- Healthy
- Interventions
- Drug: PlaceboDrug: BI-409306 25 milligram (mg) SDDrug: BI-409306 50 mg SDDrug: BI-409306 100 mg SDDrug: BI-409306 100 mg MD
- First Posted Date
- 2013-04-26
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 65
- Registration Number
- NCT01841112
- Locations
- 🇰🇷
1289.4.8201 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of
Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 1015550 Powder for Oral Solution
- First Posted Date
- 2013-04-19
- Last Posted Date
- 2016-01-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT01835899
- Locations
- 🇩🇪
1305.2.1 Boehringer Ingelheim Investigational Site, Mannheim, Germany
BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2013-04-12
- Last Posted Date
- 2015-11-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 35
- Registration Number
- NCT01830127
- Locations
- 🇺🇸
1241.30.10001 Boehringer Ingelheim Investigational Site, Deland, Florida, United States
🇩🇪1241.30.49004 Boehringer Ingelheim Investigational Site, Berlin, Germany
🇩🇪1241.30.49008 Boehringer Ingelheim Investigational Site, Bonn, Germany
Linagliptin Among Filipino Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2013-04-08
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 678
- Registration Number
- NCT01826370
- Locations
- 🇵🇭
Boehringer Ingelheim Investigational Site 42, Cardona, Rizal, Philippines
🇵🇭Boehringer Ingelheim Investigational Site 24, Las Pinas, Philippines
🇵🇭Boehringer Ingelheim Investigational Site 25, Cebu, Philippines